US equities
|
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
AAPL
$332.89
▼-0.24%
META
$741.90
▲+1.90%
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
AAPL
$332.89
▼-0.24%
META
$741.90
▲+1.90%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
AstraZeneca PLC - American Depositary Shares
(NY:
AZN
)
156.53
-0.37 (-0.24%)
Official Closing Price
Updated: 7:00 PM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about AstraZeneca PLC - American Depositary Shares
< Previous
1
2
3
4
Next >
AstraZeneca opens new global strategic R&D center in Kendall Square, Cambridge, Massachusetts
October 05, 2026
From
AstraZeneca
Via
Business Wire
18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right.
↗
September 28, 2026
Wall Street expects an even bigger rebound for this beaten-down biotech stock.
Via
The Motley Fool
Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin granted Priority Review in the US for patients with muscle-invasive bladder cancer
September 25, 2026
From
AstraZeneca
Via
Business Wire
Alnylam's Sell-Off Looks Ugly -- but Wall Street Still Sees a Much Brighter Picture
↗
September 15, 2026
Analysts think Alnylam could rebound strongly over the next 12 months.
Via
The Motley Fool
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial
September 13, 2026
From
AstraZeneca
Via
Business Wire
TAGRISSO® (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial
September 13, 2026
From
AstraZeneca
Via
Business Wire
AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears
↗
September 13, 2026
Astrazeneca (NYSE:AZN) presented Phase III data for tozorakimab in chronic obstructive pulmonary disease, or COPD, at the 2026 European Respiratory Society Congress in Barcelona, reporting...
Via
MarketBeat
Topics
ETFs
IMFINZI® (durvalumab) plus tarlatamab demonstrated a statistically significant and highly clinically meaningful improvement in overall survival and progression-free survival in 1st-line extensive-stage small cell lung cancer
September 08, 2026
From
AstraZeneca
Via
Business Wire
Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials
September 08, 2026
From
AstraZeneca
Via
Business Wire
ETCAMAH® (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer
September 04, 2026
From
AstraZeneca
Via
Business Wire
Here's Why Ionis Pharmaceuticals' Steep Sell-off Was Overdone
↗
September 03, 2026
This biotech stock looks like a great candidate to buy on the admittedly steep dip.
Via
The Motley Fool
AstraZeneca completes global license agreement for oral EGFR inhibitor ZEGFROVY® (sunvozertinib) for lung cancer
September 01, 2026
From
AstraZeneca
Via
Business Wire
Opinion: Bristol Myers Squibb Is a Buy -- but the Real Reason Why Might Surprise Investors
↗
August 29, 2026
Bristol Myers Squibb is facing down a major patent cliff, which is a problem and a huge motivating force.
Via
The Motley Fool
Topics
Intellectual Property
TEZSPIRE demonstrates positive Phase III results in eosinophilic esophagitis across both co-primary and all key secondary endpoints
August 27, 2026
From
AstraZeneca
Via
Business Wire
A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
August 26, 2026
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:BNTX),(NYSE:AZN),(NASDAQ:MRNA),(NYSE:BMY) EQNX::TICKER_END
Via
FinancialNewsMedia
A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
August 26, 2026
A New Generation of Personalized Cancer Treatments Could Open a Multibillion-Dollar Market for Precision Oncology
From
MarketNewsUpdates.com
Via
GlobeNewswire
Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
August 19, 2026
News Provided by USA News Group on behalf of MindWalk Holdings Corp.
From
USA News Group
Via
GlobeNewswire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial
August 17, 2026
From
AstraZeneca
Via
Business Wire
TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO
August 17, 2026
From
AstraZeneca
Via
Business Wire
Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing
↗
August 16, 2026
Yes, Alnylam has had some bad news. But the bad news isn't as horrible as many think.
Via
The Motley Fool
Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen?
↗
August 13, 2026
There's a good reason why AstraZeneca tanked when merger rumors hit the Street.
Via
The Motley Fool
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN
August 04, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN
July 28, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Astrazeneca Q2 Earnings Call Highlights
↗
July 27, 2026
Astrazeneca (NYSE:AZN) reported first-half 2026 revenue growth of 6% at constant exchange rates, or 11% excluding the effects of generic competition on Farxiga and Brilinta, while core earnings per...
Via
MarketBeat
Topics
ETFs
Earnings
Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers
July 27, 2026
From
AstraZeneca
Via
Business Wire
AstraZeneca results: H1 and Q2 2026
July 27, 2026
From
AstraZeneca
Via
Business Wire
AZN Investors Have Opportunity to Join AstraZeneca PLC Fraud Investigation with the Schall Law Firm
July 22, 2026
From
The Schall Law Firm
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AstraZeneca PLC- AZN
July 21, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN
July 14, 2026
From
Pomerantz LLP
Via
GlobeNewswire
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions
↗
July 13, 2026
Wainua missed its Phase 3 endpoint, hitting Ionis Pharmaceuticals hard while AstraZeneca absorbed the blow easily, boosting rivals BridgeBio, Pfizer and Alnylam Pharmaceuticals.
Via
MarketBeat
< Previous
1
2
3
4
Next >
